ArticleCells2013
Targeting neutrophil apoptosis for enhancing the resolution of inflammation.
Article in Cells, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Relationship between neutrophil to lymphocyte ratio and diabetic peripheral neuropathy: a systematic review and meta-analysis.European journal of medical research · 2023Pooled it
- Cardiac repair after myocardial infarction: A two-sided role of inflammation-mediated.Frontiers in cardiovascular medicine · 2022Pooled it
- Selenium and Selenoproteins in Neutrophil Functions.Biological trace element research · 2026Review
- Association Between Neutrophil-to-Lymphocyte Ratio and Mortality Risk Among Patients With Hyperlipidemia Across Different Glycemic Status: A Longitudinal Cohort Study From NHANES 1999-2018.Reviews in cardiovascular medicine · 2026Article
- Linoleoyl-lysophosphatidylcholine drives non-inflammatory apoptosis in neutrophils via lipid rafts.Frontiers in immunology · 2026Article
- Cytoprotective effect of prostacyclin on hepatic ischemia-reperfusion injury.World journal of methodology · 2025Review
- Compatible Solutes Prevent Lung Inflammation and Reduction in CFTR Induced by Combustion-Derived Nanoparticles in Human and Rodent Experimental Systems.International journal of molecular sciences · 2025Article
- TRAIL and RIPK3 Do Not Predict Mortality and Acute Kidney Injury in Critically Ill Patients at Admission to the Intensive Care Unit-A Single-Center Cohort Study.International journal of molecular sciences · 2025Article
- Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis.Journal of advanced research · 2025Review
- Selenoproteome depletion enhances oxidative stress and alters neutrophil functions in Citrobacter rodentium infection leading to gastrointestinal inflammation.Free radical biology & medicine · 2025Article
- Treatment with lipoxin AInflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Article
- Treatment with lipoxin A 4 improves influenza A infection outcome through macrophage reprogramming, anti-inflammatory and pro-resolutive responses.Research square · 2024Article
- Immunomodulation for Tissue Repair and Regeneration.Tissue engineering and regenerative medicine · 2023Review
- Neutrophils as a potential therapeutic target in Alzheimer's disease.Frontiers in immunology · 2023Review
- "Rogue" neutrophil-subset [DEspR+CD11b+/CD66b+] immunotype is an actionable therapeutic target for neutrophilic inflammation-mediated tissue injury -Frontiers in immunology · 2022Article
- Inflammatory Response to Regulated Cell Death in Gout and Its Functional Implications.Frontiers in immunology · 2022Review
- In Vivo Efficacy of Neutrophil-Mediated Bone Regeneration Using a Rabbit Calvarial Defect Model.International journal of molecular sciences · 2021Article
- CD300a contributes to the resolution of articular inflammation triggered by MSU crystals by controlling neutrophil apoptosis.Immunology · 2021Article
- Role of specialized pro-resolving lipid mediators in pulmonary inflammation diseases: mechanisms and development.Respiratory research · 2021Review
- Importance of hematological parameters for micro- and macrovascular outcomes in patients with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study.Cardiovascular diabetology · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resolution of acute inflammation is an active process that requires inhibition of further leukocyte recruitment and removal of leukocytes from inflamed sites. Emigrated neutrophils undergo apoptosis before being removed by scavenger macrophages. Recent studies using a variety of gene knockout, transgenic and pharmacological strategies in diverse models of inflammation established neutrophil apoptosis as a critical control point in resolving inflammation. Analysis of death mechanisms revealed distinct features in executing the death program in neutrophils, which can be exploited as targets for controlling the lifespan of neutrophils. Indeed, anti-inflammatory and pro-resolution lipid mediators derived from essential fatty acids, such as lipoxin A4 and resolvin E1, autacoids and proteins, such as annexin A1 and TRAIL, and cyclin-dependent kinase inhibitors, can enhance the resolution of inflammation through induction of neutrophil apoptosis and promoting their removal by efferocytosis. In this review, we discuss recent advances in understanding the molecular basis of these actions, highlighting the potential of therapeutic induction of neutrophil apoptosis for dampening neutrophil-mediated tissue injury and inflammation underlying a variety of diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.